ArticleBioMed research international2013
Circulating microRNAs and kallikreins before and after radical prostatectomy: are they really prostate cancer markers?
Article in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Circulating microRNAs as novel biomarkers in the diagnosis of prostate cancer: a systematic review and meta-analysis.International urology and nephrology · 2016Pooled it
- Extracellular miRNA-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations.Oncotarget · 2016Pooled it
- Article
- miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review.Journal of the Egyptian National Cancer Institute · 2024Review
- Circulating microRNAs as Reliable Tumor Biomarkers: Opportunities and Challenges Facing Clinical Application.The Journal of pharmacology and experimental therapeutics · 2023Review
- Correlations between serum levels of microRNA-148a-3p and microRNA-485-5p and the progression and recurrence of prostate cancer.BMC urology · 2022Article
- The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.Journal of cancer research and clinical oncology · 2022Review
- CircLRP6 contributes to prostate cancer growth and metastasis by binding to miR-330-5p to up-regulate NRBP1.World journal of surgical oncology · 2021Article
- The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p.Cancer biomarkers : section A of Disease markers · 2021Article
- The Influence of Radical Prostatectomy on the Expression of Cell-Free MiRNA.Diagnostics (Basel, Switzerland) · 2020Article
- The auxiliary diagnostic value of prostate-specific antigen and α-methylacyl-CoA racemase in prostate cancer.Oncology letters · 2020Article
- Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer.Scientific reports · 2020Article
- MicroRNA-939 Directly TargetsOncoTargets and therapy · 2020Article
- Endorectal power Doppler/grayscale ultrasound-guided biopsies vs. multiparametric MRI/ultrasound fusion-guided biopsies in males with high risk of prostate cancer: A prospective cohort study.Experimental and therapeutic medicine · 2019Article
- Circulating microRNAs in plasma before and after radical prostatectomy.Urologic oncology · 2019Article
- Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy.The Prostate · 2019Article
- Research status and progress of the RNA or protein biomarkers for prostate cancer.OncoTargets and therapy · 2019Review
- The translational potential of microRNAs as biofluid markers of urological tumours.Nature reviews. Urology · 2016Review
- MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer.International journal of molecular sciences · 2016Review
- Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role.OncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of our study was to monitor serum levels of two miRNAs (miR-21 and miR-141) and three KLKs (hK3/PSA, hK11, and hK13) before and 1, 5, and 30 days after radical prostatectomy, in order to characterize their fluctuations after surgery. 38 patients with prostate cancer were included. miR-21 and miR-141 were quantified through real-time PCR, while ELISA assays were used to quantify hK3 (PSA), hK11, and hK13. Both miR-21 and miR-141 showed a significant increase at the 5th postoperative day, after which a gradual return to the preoperative levels was recorded. These findings suggest that miR-21 and miR-141 could be involved in postsurgical inflammatory processes and that radical prostatectomy does not seem to alter their circulating levels. Postoperative serum kallikreins showed a significant decrease, highlighting the potential usefulness of kallikreins apart from PSA as potential prostate cancer markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.